BioSpace News Archive

Tiziana Life Sciences announced that Dr. Tanuja Chitnis, MD, Professor of Neurology and the Principal investigator of the clinical study at the at the Brigham and Women’s Hospital, Boston, MA., will be presenting a poster discussing clinical data from a patient with secondary progressive Multiple Sclerosis, who was treated with intranasal foralumab for six months.

Hoffmann-La Roche Limited is pleased to announce that Health Canada authorized VABYSMO® for the treatment of neovascular age-related macular degeneration and diabetic macular edema, two of the leading causes of vision loss among Canadians.

Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that management will present at the following investor conferences.

Karyopharm Therapeutics Inc. announced that the Company’s senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 9:30 a.m. ET in New York, NY.

ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types.

CytoSorbents Corporation today announced that following a successful pilot program in three countries, the Company has signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (Nikkiso) to distribute their PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries.

SciNeuro Pharmaceuticals (SciNeuro), a leader in the discovery and development of innovative therapeutics for the treatment of CNS diseases, today announced the execution of an exclusive, worldwide license and option agreement with GlaxoSmithKline (GSK).

Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV.

Wide range of research across tumor types underscores Servier’s commitment to discovering novel approaches to addressing difficult-to-treat cancers.

Bristol Myers Squibb announced positive results from the Phase 2 PAISLEY study evaluating deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, compared to placebo in patients with moderate to severe systemic lupus erythematosus.